Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 2/20 | 0.56 |
| ▸ | KRAS | P01116 | 6/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31238612 | 0.93 | NTSR1 (0.58) | NTSR1KRASPSMB1PSMB5HTR2A | |
| SCHEMBL23631648 | 0.85 | NTSR1 (0.60) | NTSR1KRASPSMB1PSMB5HTR2A | |
| SCHEMBL31238626 | 0.82 | KMT2A (0.61) | NTSR1TERTIDO1ATMKDM4E | |
| SCHEMBL416378 | 0.80 | ALOX5 (0.49) | NTSR1KRASHTR2AHTR2C | |
| SCHEMBL418013 | 0.80 | KMT2A (0.60) | NTSR1KRASHTR2AHTR2C | |
| SCHEMBL19100386 | 0.77 | KMO (0.56) | NTSR1KRASHTR2AHTR2CLMNA | |
| SCHEMBL29758270 | 0.77 | KMO (0.56) | NTSR1KRASHTR2AHTR2CLMNA | |
| SCHEMBL23631602 | 0.74 | KDM4E (0.48) | NTSR1KRASPSMB1PSMB5KDM4E | |
| SCHEMBL24480089 | 0.73 | ALDH1A1 (0.62) | NTSR1KRASLMNAKDM4EPOLB | |
| SCHEMBL2008953 | 0.73 | HTR2A (0.55) | NTSR1KRASHTR2AHTR2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2024-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, NOD1 | NTSR1 2847/4885KRAS 2801/4885PSMB1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.